Sagimet BiosciencesSTU:0O2 +1.66%10 Current Ratio is 20.33 as of Mar. 2026, which is 0% below its 10-year median of 20.35. GuruFocus rates STU:0O2 with a GF Score™ of 10/100. The stock has 2 warning signs investors should review. Among 1,413 Biotechnology companies, Sagimet Biosciences ranks better than 92.5% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Sagimet Biosciences's current ratio for the quarter that ended in Mar. 2026 was 20.33.
Sagimet Biosciences has a current ratio of 20.33. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Sagimet Biosciences's Current Ratio or its related term are showing as below:
STU:0O2'
s Current Ratio Range Over the Past 10 Years
Min: 4.04 Med: 20.35 Max: 43.12
Current: 20.34
During the past 7 years, Sagimet Biosciences's highest Current Ratio was 43.12. The lowest was 4.04. And the median was 20.35.
STU:0O2's Current Ratio is ranked better than 92.5% of 1413
companies
in the Biotechnology industry
Industry Median: 3.89
vs STU:0O2: 20.34
Sagimet Biosciences (STU:0O2) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Sagimet Biosciences Current Ratio Related Terms
Sagimet Biosciences Current Ratio Historical Data
* Premium members only.
The historical data trend for Sagimet Biosciences's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:0O2 vs NGNE, UPB, STTK: Current Ratio Comparison
For the Biotechnology subindustry, Sagimet Biosciences's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sagimet Biosciences Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sagimet Biosciences's Current Ratio distribution charts can be found below:
* The bar in red indicates where Sagimet Biosciences's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sagimet Biosciences (STU:0O2) has a Current Ratio of 20.33 as of Mar. 2026. This is near median its historical median of 20.35. Over the past decade, Sagimet Biosciences' Current Ratio has ranged from 4.04 to 43.12. According to the industry distribution chart, Sagimet Biosciences ranks #106 out of 1413 companies in the Biotechnology industry, placing it in the top 7.5%.
Is Sagimet Biosciences' Current Ratio too high?
Sagimet Biosciences' current Current Ratio of 20.33 is near median its 10-year median of 20.35. Over the past 10 years, this metric has ranged from a low of 4.04 to a high of 43.12. The Biotechnology industry median Current Ratio is 3.89. Sagimet Biosciences' value of 20.33 is 422.6% above this industry median. Based on the distribution chart, Sagimet Biosciences ranks #106 out of 1413 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Sagimet Biosciences has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Sagimet Biosciences' Current Ratio compare to NGNE and UPB?
According to the Biotechnology industry distribution chart, Sagimet Biosciences ranks #106 out of 1413 companies for Current Ratio. This places Sagimet Biosciences in the top 8% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.89. Sagimet Biosciences' value of 20.33 is 422.6% above this benchmark. Historically, Sagimet Biosciences' own Current Ratio has ranged from 4.04 to 43.12 over the past decade. While the company's 10-year median is 20.35 vs. the industry median of 3.89, Sagimet Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,413 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sagimet Biosciences's current Current Ratio of 20.33 is 422.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sagimet Biosciences's current Current Ratio is 20.33, which is near median its own 10-year median of 20.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sagimet Biosciences stock overvalued right now?
Sagimet Biosciences (STU:0O2) has a current Current Ratio of 20.33. The current Current Ratio is 20.33, which is near median its 10-year median of 20.35 and 422.6% above the Biotechnology industry median of 3.89. Sagimet Biosciences' overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Sagimet Biosciences (STU:0O2), the current Current Ratio is 20.33 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
10GF Score
Get the complete analysis for STU:0O2
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:0O2 has been successfully added to your 
